FIELD: biotechnology.
SUBSTANCE: invention relates to the use of a histamine-producing strain of lactic acid bacteria for the prevention, inhibition, treatment or reduction of the risk of recurrence of colorectal cancer associated with inflammation. Proposed is the use of a histamine-producing strain of lactic acid bacteria containing an active histidine operon and producing diacylglycerol kinase (DagK) for the prevention, inhibition, treatment or reduction of the risk of recurrence associated with inflammation of colorectal cancer. Also proposed is the Lactobacillus reuteri strain deposited in DSMZ under accession number DSM 32273, with the said strain containing an active histidine operon and producing DagK. The specified strain can be used as a drug for the prevention, inhibition, treatment or reduction of the risk of recurrence of colorectal cancer associated with inflammation.
EFFECT: invention can be used in treatment of malignant tumors, in particular colorectal cancer associated with inflammation.
6 cl, 4 tbl, 9 ex, 10 dwg
